ArticleJournal of translational medicine2016
An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma.
Article in Journal of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 50 citations in OpenAlex.
- Deep Learning-Based Analysis of Gene Expression Data and Gene-Related Information in Pediatric Surgical Oncology: A Scoping Review.Cancer medicine · 2026Article
- Regulatory non-coding somatic mutations as drivers of neuroblastoma.British journal of cancer · 2025Article
- Genetic Risk Profiling Reveals Altered Glycosyltransferase Expression as a Predictor for Patient Outcome in Neuroblastoma.Journal of clinical medicine · 2025Article
- Fine construction of gene coexpression network analysis using GTOM and RECODE detected a critical module of neuroblastoma stages 4 and 4S.Hereditas · 2024Article
- Integrative genomic analyses identify neuroblastoma risk genes involved in neuronal differentiation.Human genetics · 2024Article
- SAP30, an oncogenic driver of progression, poor survival, and drug resistance in neuroblastoma.Molecular therapy. Nucleic acids · 2024Article
- From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models.Journal of translational medicine · 2024Article
- Phenotyping neuroblastoma cells through intelligent scrutiny of stain-free biomarkers in holographic flow cytometry.APL bioengineering · 2023Article
- Identification of a novel eighteen-gene signature of recurrent metastasis neuroblastoma.Journal of molecular medicine (Berlin, Germany) · 2023Article
- An online survival predictor in glioma patients using machine learning based on WHO CNS5 data.Frontiers in neurology · 2023Article
- FGFR1 is a potential therapeutic target in neuroblastoma.Cancer cell international · 2022Article
- Ferroptosis-related gene signatures in neuroblastoma associated with prognosis.Frontiers in cell and developmental biology · 2022Article
- Single-cell transcriptomics of neuroblastoma identifies chemoresistance-associated genes and pathways.Computational and structural biotechnology journal · 2022Article
- Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of NeuroblastomaFrontiers in oncology · 2021Article
- Prognostic Signature of Immune Genes and Immune-Related LncRNAs in Neuroblastoma: A Study Based on GEO and TARGET Datasets.Frontiers in oncology · 2021Article
- Identification of the Novel Methylated Genes' Signature to Predict Prognosis in INRG High-Risk Neuroblastomas.Journal of oncology · 2021Article
- Identification of novel prognostic markers of survival time in high-risk neuroblastoma using gene expression profiles.Oncotarget · 2020Article
- Gene Expression Signature of Acquired Chemoresistance in Neuroblastoma Cells.International journal of molecular sciences · 2020Article
- Article
- Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma.Journal of cellular and molecular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognosis of children with metastatic stage 4 neuroblastoma (NB) has remained poor in the past decade. PATIENTS AND
methodsUsing microarray analyses of 342 primary tumors, we here developed and validated an easy to use gene expression-based risk score including 18 genes, which can robustly predict the outcome of stage 4 patients.
resultsThis classifier was a significant predictor of overall survival in two independent validation cohorts [cohort 1 (n = 214): P = 6.3 × 10(-5); cohort 2 (n = 27): P = 3.1 × 10(-2)]. The prognostic value of the risk score was validated by multivariate analysis including the established markers age and MYCN status (P = 0.027). In the pooled validation cohorts (n = 241), integration of the risk score with the age and/or MYCN status identified subgroups with significantly differing overall survival (ranging from 35 to 100 %).
conclusionTogether, the 18-gene risk score classifier can identify patients with stage 4 NB with favorable outcome and may therefore improve risk assessment and treatment stratification of NB patients with disseminated disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.